» Articles » PMID: 9713065

Effects of Single, Short-term Exposures of Human Retinal Pigment Epithelial Cells to Thiotepa or 5-fluorouracil: Implications for the Treatment of Proliferative Vitreoretinopathy

Overview
Journal Br J Ophthalmol
Specialty Ophthalmology
Date 1998 Aug 26
PMID 9713065
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To investigate the effects of single, short-term (5 or 30 minutes) exposures to thiotepa or 5-fluorouracil (5-FU) on collagen lattice contraction and retinal pigment epithelial (RPE) cell proliferation.

Methods: For collagen contraction studies, RPE cells seeded into free floating type I collagen lattices were exposed to single 5 or 30 minute treatments with thiotepa (0.06-4 mg/ml), or 5-FU (0.25-25 mg/ml), or phosphate buffered saline alone as a control. For proliferation studies, RPE cell monolayers were similarly exposed to these agents. The degree of contraction, effects on cell number, and viability were determined up to 14 days after treatment.

Results: Contraction of collagen lattices containing RPE cells and proliferation of RPE cells were significantly inhibited (p < 0.05) by thiotepa and 5-FU at concentrations above 0.06 mg/ml and 0.25 mg/ml respectively (for both 5 and 30 minute treatments), compared with controls. Cell death did not occur except for exposure of the RPE cells in collagen lattices to the highest concentration of thiotepa (4 mg/ml).

Conclusion: It was concluded that single 5 or 30 minute exposures to thiotepa or 5-FU significantly inhibited collagen contraction and the proliferation of RPE cells. These findings suggest that short, single, non-toxic exposures to thiotepa or 5-FU which can be reproduced clinically may be useful in the modulation of proliferative vitreoretinopathy.

Citing Articles

Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis.

Chen C, Chen P, Liu X, Li H Front Med (Lausanne). 2021; 8:790460.

PMID: 34917641 PMC: 8669826. DOI: 10.3389/fmed.2021.790460.


In Vitro Cell Models for Ophthalmic Drug Development Applications.

Shafaie S, Hutter V, Cook M, Brown M, Chau D Biores Open Access. 2016; 5(1):94-108.

PMID: 27158563 PMC: 4845647. DOI: 10.1089/biores.2016.0008.


Epithelial-to-Mesenchymal Transition of RPE Cells In Vitro Confers Increased β1,6-N-Glycosylation and Increased Susceptibility to Galectin-3 Binding.

Priglinger C, Obermann J, Szober C, Merl-Pham J, Ohmayer U, Behler J PLoS One. 2016; 11(1):e0146887.

PMID: 26760037 PMC: 4712018. DOI: 10.1371/journal.pone.0146887.


Quinotrierixin inhibits proliferation of human retinal pigment epithelial cells.

Chen C, Wang J, Li J, Yu Q, Zhang S Mol Vis. 2013; 19:39-46.

PMID: 23335849 PMC: 3541046.


The clinical applications of fluorouracil in ophthalmic practice.

Abraham L, Selva D, Casson R, Leibovitch I Drugs. 2007; 67(2):237-55.

PMID: 17284086 DOI: 10.2165/00003495-200767020-00005.


References
1.
MACHEMER R, Laqua H . Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol. 1975; 80(1):1-23. DOI: 10.1016/0002-9394(75)90862-4. View

2.
Blumenkranz M, Hartzer M, Hajek A . Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol. 1987; 105(3):396-9. DOI: 10.1001/archopht.1987.01060030116039. View

3.
Ehrlich D . The management of pterygium. Ophthalmic Surg. 1977; 8(2):23-30. View

4.
Ericson L, Karlberg B, ROSENGREN B . Trials of intravitreal injections of chemotherapeutic agents in rabbits. Acta Ophthalmol (Copenh). 1964; 42(4):721-6. DOI: 10.1111/j.1755-3768.1964.tb01723.x. View

5.
Occleston N, ALEXANDER R, Mazure A, Larkin G, Khaw P . Effects of single exposures to antiproliferative agents on ocular fibroblast-mediated collagen contraction. Invest Ophthalmol Vis Sci. 1994; 35(10):3681-90. View